← All trials
NCT05437029
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 15, 2022
- Primary completion
- Oct 15, 2022
- Completion date
- Nov 1, 2022
- First posted
- Jun 29, 2022
- Last posted
- Jul 5, 2022
- Enrollment
- 24
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of LouisvilleLead sponsor
- University of LouisvilleOverall official - principal investigator
- University of LouisvilleSponsor investigator
- Department of DefenseCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.